IL245407B - Salts of 1-(3-methyl-2-oxo-3,2-dihydro-3,1-benzoxazol-6-yl)-4,2-dioxo-3-[(r1)-4-(trifluoromethyl)-3 2-dihydro-1h-indan-1-yl]-4,3,2,1-tetrahydropyrimidine-5-carboxylic acid - Google Patents

Salts of 1-(3-methyl-2-oxo-3,2-dihydro-3,1-benzoxazol-6-yl)-4,2-dioxo-3-[(r1)-4-(trifluoromethyl)-3 2-dihydro-1h-indan-1-yl]-4,3,2,1-tetrahydropyrimidine-5-carboxylic acid

Info

Publication number
IL245407B
IL245407B IL24540716A IL24540716A IL245407B IL 245407 B IL245407 B IL 245407B IL 24540716 A IL24540716 A IL 24540716A IL 24540716 A IL24540716 A IL 24540716A IL 245407 B IL245407 B IL 245407B
Authority
IL
Israel
Prior art keywords
dihydro
trifluorethyl
tetrahydropyrimidin
benzoxazol
inden
Prior art date
Application number
IL24540716A
Other languages
English (en)
Hebrew (he)
Other versions
IL245407A0 (en
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of IL245407A0 publication Critical patent/IL245407A0/en
Publication of IL245407B publication Critical patent/IL245407B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL24540716A 2013-11-08 2016-05-01 Salts of 1-(3-methyl-2-oxo-3,2-dihydro-3,1-benzoxazol-6-yl)-4,2-dioxo-3-[(r1)-4-(trifluoromethyl)-3 2-dihydro-1h-indan-1-yl]-4,3,2,1-tetrahydropyrimidine-5-carboxylic acid IL245407B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13192177 2013-11-08
PCT/EP2014/073801 WO2015067652A1 (de) 2013-11-08 2014-11-05 Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure

Publications (2)

Publication Number Publication Date
IL245407A0 IL245407A0 (en) 2016-06-30
IL245407B true IL245407B (en) 2019-10-31

Family

ID=49552231

Family Applications (1)

Application Number Title Priority Date Filing Date
IL24540716A IL245407B (en) 2013-11-08 2016-05-01 Salts of 1-(3-methyl-2-oxo-3,2-dihydro-3,1-benzoxazol-6-yl)-4,2-dioxo-3-[(r1)-4-(trifluoromethyl)-3 2-dihydro-1h-indan-1-yl]-4,3,2,1-tetrahydropyrimidine-5-carboxylic acid

Country Status (32)

Country Link
US (1) US9926305B2 (cg-RX-API-DMAC7.html)
EP (1) EP3066097B1 (cg-RX-API-DMAC7.html)
JP (1) JP6446051B2 (cg-RX-API-DMAC7.html)
KR (1) KR102351418B1 (cg-RX-API-DMAC7.html)
CN (1) CN105658647B (cg-RX-API-DMAC7.html)
AP (1) AP2016009181A0 (cg-RX-API-DMAC7.html)
AU (1) AU2014345599B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016010253A8 (cg-RX-API-DMAC7.html)
CA (1) CA2929780C (cg-RX-API-DMAC7.html)
CL (1) CL2016001096A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119520T1 (cg-RX-API-DMAC7.html)
DK (1) DK3066097T3 (cg-RX-API-DMAC7.html)
EA (1) EA033132B1 (cg-RX-API-DMAC7.html)
ES (1) ES2645480T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171603T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035021T2 (cg-RX-API-DMAC7.html)
IL (1) IL245407B (cg-RX-API-DMAC7.html)
LT (1) LT3066097T (cg-RX-API-DMAC7.html)
MA (1) MA39020A1 (cg-RX-API-DMAC7.html)
ME (1) ME02907B (cg-RX-API-DMAC7.html)
MX (1) MX366848B (cg-RX-API-DMAC7.html)
MY (1) MY190108A (cg-RX-API-DMAC7.html)
NO (1) NO3066097T3 (cg-RX-API-DMAC7.html)
PH (1) PH12016500853B1 (cg-RX-API-DMAC7.html)
PL (1) PL3066097T3 (cg-RX-API-DMAC7.html)
PT (1) PT3066097T (cg-RX-API-DMAC7.html)
RS (1) RS56509B1 (cg-RX-API-DMAC7.html)
SA (1) SA516371082B1 (cg-RX-API-DMAC7.html)
SI (1) SI3066097T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000170A1 (cg-RX-API-DMAC7.html)
UA (1) UA117686C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015067652A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CA3061444A1 (en) * 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
WO2022135502A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
KR20240170943A (ko) * 2022-04-05 2024-12-05 스코프라 시앙스 쌍테 에 휴마이네스 에스.에.쎄. 혈전성 또는 혈전색전성 장애에서 혈전의 선택적인 해소에 사용하기 위한 키마제의 억제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032881A1 (en) * 2000-10-19 2002-04-25 Nippon Kayaku Kabushiki Kaisha Novel remedies or preventives for angiostenosis
AT511788A1 (de) 2011-07-29 2013-02-15 Georg Dr Gaul Vorrichtung zur vorgebbaren anordnung eines stents
EP2822405A4 (en) * 2012-03-05 2015-04-29 Gratuk Technologies Pty Ltd FOOD SUPPLEMENTS
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
CA2929763A1 (en) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors

Also Published As

Publication number Publication date
PH12016500853B1 (en) 2021-03-24
CA2929780A1 (en) 2015-05-14
EA033132B1 (ru) 2019-08-30
US20160289220A1 (en) 2016-10-06
US9926305B2 (en) 2018-03-27
EP3066097B1 (de) 2017-08-16
AU2014345599A1 (en) 2016-05-19
HUE035021T2 (en) 2018-03-28
HRP20171603T1 (hr) 2017-12-01
HK1222171A1 (zh) 2017-06-23
NZ719532A (en) 2021-06-25
SI3066097T1 (sl) 2017-12-29
CY1119520T1 (el) 2018-03-07
LT3066097T (lt) 2018-02-12
UA117686C2 (uk) 2018-09-10
JP6446051B2 (ja) 2018-12-26
MA39020A1 (fr) 2017-04-28
CL2016001096A1 (es) 2016-12-23
PL3066097T3 (pl) 2018-01-31
CN105658647B (zh) 2019-09-06
KR20160078980A (ko) 2016-07-05
RS56509B1 (sr) 2018-02-28
CA2929780C (en) 2022-03-22
NO3066097T3 (cg-RX-API-DMAC7.html) 2018-01-13
BR112016010253A2 (pt) 2017-08-08
DK3066097T3 (da) 2017-11-06
CN105658647A (zh) 2016-06-08
TN2016000170A1 (en) 2017-10-06
PT3066097T (pt) 2017-11-10
PH12016500853A1 (en) 2016-06-20
KR102351418B1 (ko) 2022-01-17
JP2016535096A (ja) 2016-11-10
MX366848B (es) 2019-07-26
WO2015067652A1 (de) 2015-05-14
SA516371082B1 (ar) 2019-05-16
MX2016005971A (es) 2016-08-11
ES2645480T3 (es) 2017-12-05
AU2014345599B2 (en) 2019-02-14
BR112016010253A8 (pt) 2021-06-22
EP3066097A1 (de) 2016-09-14
ME02907B (me) 2018-04-20
AP2016009181A0 (en) 2016-04-30
MY190108A (en) 2022-03-29
EA201600381A1 (ru) 2016-10-31
IL245407A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
ITMI20131102A1 (it) Gestione harq-ack per subframe di dowlink non intenzionali
EP3042261A4 (en) Managing power feeds through waveform monitoring
SMT201700003B (it) Didropiridoni come inibitori del fattore xia
EP3001864A4 (en) Contextual heart rate monitoring
EP2773398A4 (en) SYRINGE WITH AN ANTISEPTIC CAP
PT3010910T (pt) Compostos de pirimidinadiona contra as condições cardíacas
CO7061071A2 (es) Procesos para la preparación de (s)-1-(3-etoxi-4-metoxifenil)-2-metansulfoniletilamina
EP2773566A4 (en) APPLICATORS FOR STORING, STERILIZING AND DISTRIBUTING A LIABILITY
HRP20160250T1 (hr) Postupak za pripravu 2-(2,3-dimetilfenil)-1-propanala s kloracetonom
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
CL2017001467A1 (es) Compuestos de dihidropirimidin - 2 - ona y sus usos médicos
EP2889016A4 (en) DENTAL SYRINGE
IL245407B (en) Salts of 1-(3-methyl-2-oxo-3,2-dihydro-3,1-benzoxazol-6-yl)-4,2-dioxo-3-[(r1)-4-(trifluoromethyl)-3 2-dihydro-1h-indan-1-yl]-4,3,2,1-tetrahydropyrimidine-5-carboxylic acid
EP2973109A4 (en) DYNAMIC WORKFLOW FOR SUPERBILLCODING
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
EP3212705A4 (en) Oxalic acid diamides as modifiers for polyolefin catalysts
ITMI20130722A1 (it) Macchina di riempimento combinata, dotata di funzione di pesatura e di gestione del volume, per camere bianche
ITMI20130708A1 (it) Macchina di riempimento combinata, dotata di funzione di pesatura e di gestione del volume, per camere bianche
SI2656843T1 (sl) Estri bendamustina in povezane spojine ter njihova medicinska uporaba
BR112017007509A2 (pt) Processo para a preparação de 1-(3,5-dicloro-4- fluoro-fenil)-2,2,2-trifluoro-etanona
MX373227B (es) Sales farmacéuticamente aceptables de enantiómeros de pirlindol para utilizarse en medicina.
GB2529601B (en) Dynamic management of integration protocols
GB201704861D0 (en) Contextual workflow management
BR112015028948A2 (pt) gerenciamento de entrega de medicamento
FR3003479B1 (fr) Distributeur de produit fluide rechargeable.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed